First quarter of 2018

Bayer: Operational business held back by currency effects - Major progress with Monsanto acquisition

Group sales increase by 2.0 percent (Fx & portfolio adj.) to 9.138 billion euros / EBITDA before special items down year on year at 2.896 billion euros due to currency effects - level with prior-year quarter on a currency-adjusted basis / Sales increase at Pharmaceuticals (Fx & portfolio adj.) / Consumer Health down year on year, as expected / Sales of Crop Science match strong prior-year quarter (Fx & portfolio adj.) / Animal Health raises sales (Fx & portfolio adj.) and earnings / Net income declines by 6.2 percent to 1.954 billion euros / Core earnings per share down 1.3 percent at 2.28 euros / European Commission and additional regulators conditionally approve Monsanto acquisition / Currency adjusted Group outlook for 2018 confirmed more